Search filters
Filters
Clear All

Phase

  • 24
  • 4
  • 23
  • 1
  • 31
  • 1
  • 10
  • 97
  • 62
  • 1
  • 1
  • 95
  • 97

Found 97 Vision Loss trials

A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

APOLLO-B: A Phase 3 Randomized Double-blind Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

99 years or below
All genders
TBD
Learn More

A Phase 3 Double-Blind Randomized Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects with Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) AG348-C-018

99 years or below
All genders
Phase 3
To compare the effect of mitapivat versus placebo on transfusion burden in subjects with alpha- or beta-transfusiondependent thalassemia (TDT) Transfusion reduction response (TRR), defined as a 50% reduction in transfused red blood cell (RBC) units with a reduction of greater that or equal to 2 units of transfused RBCs in …
Learn More

ABC008-IBM-201: A Phase II/III Randomized Double-blind Placebo-controlled Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis

99 years or below
All genders
dosing of ABC008 in subjects with inclusion body myositis (IBM).
Learn More

A Multicenter Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy

99 years or below
All genders
Phase 3
The trial will enroll subjects who have had an inadequate response (IR) to prior biologic therapy (bio-IR). The bio-IR population is defined as subjects with documented intolerance or inadequate response to one or more of the approved biologics for UC (infliximab, adalimumab, golimumab, and/or vedolizumab).
Learn More

UPCC 03120: Randomized Double-Blind Phase 3 Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)

99 years or below
All genders
TBD
Learn More

A Randomized Double-blind Placebo-controlled Phase 1/2 Study to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Exploratory Efficacy of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

99 years or below
All genders
Phase 1
TBD
Learn More

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

18 years or above
All genders
Phase 2
Interventional
The purpose of this study is to investigate the effects of an investigational medication in adults with type II diabetes mellitus who are overweight or obese. This study focuses on individuals with weight-related health conditions.The study evaluates the safety and effectiveness of the investigational medication. It assesses changes in blood …
Check Eligibility
Multicenter randomized double-blind parallel-group add-on superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )

Multicenter randomized double-blind parallel-group add-on superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera )

99 years or below
All genders
Phase 3
This is a study to find out whether patients with active forms of Relapsing Multiple Sclerosis (RMS) who are treated with dimethyl fumarate (Tecfidera®) can be treated better by the addition of ponesimod (study drug). The purpose is also to evaluate the effect on disability and the safety of these …
Learn More

A Multi-Center Randomized Double-blind Placebo-controlled Dose-finding Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

99 years or below
All genders
Phase 2
Please see section 1 of the full protocol
Learn More

A Multicenter Randomized Double-Blind Placebo-Controlled Operationally Seamless Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata BRAVE-AA1

99 years or below
All genders
Phase 3
To evaluate the effectiveness of 4-mg baricitinib in significant increase in hair regrowth in patients with severe AA To describe the effectiveness of 4-mg baricitinib in achieving regrowth as assessed by physician assessed signs and symptoms of AA Mean percentage change from baseline to Week 52 in SALT score. Proportion …
Learn More
51 - 60 of 97